Handbook Generic Development
Master Formula & Manufacturing Processes
Title 17 - Part 3
Locum International Press.
Volume 17 - (Part 3)
Special Drug Development Series on
CD ROM
A Glimpse into the Future
This unique 10 part Series in the Handbook of Pharmaceutical Generic Development
provides in each of the series ten CDs consisting of ten
individual state-of-the-art real life commercial Master
Formulations together with the full manufacturing process. Title 17 Series
opens a window into the associations research and development product
pipeline. Allows researchers to view data and upgrade to the full Title
21 CMC as described in 'special features').
All key processing and control details highlighted. Title 21 CMC are authoritatively
written in a practical hands-on manner by pharma industry experts to the
level of both FDA and MCA/EU commercially approved manufacturing processes,
highlighting the wide variety of technical documentation and product development
expertise.
Formula and processes in the series are currently in production in the
US or EU or both. Product and process specifications and quantities are
exact commercial amounts.
| 1. Glipizide ER 5, 10mg Tablets |
| 2. Gemfibrozil 600mg Tablets |
| 3. Ofloxacin 100, 200, 400 mg Tablets |
| 4. Naproxen Na 220 mg Tablets |or| Carbidopa and Levodopa ER. Tablets 50 mg/200 mg |
| 5. Buspirone HCl 5, 10 mg Tablets |
| 6. Tolmetin Tablets |
| 7. Trazadone 50, 100, 150 mg Tablets |
| 8. Furosemide 40 mg Tablets |
| 9. Naphazoline HCl Nasal Drops |
| 10.Flunisolide Hemihydrate Nasal Solution |
Complete
CD series is available as a ten part volume series of 10 CDs with
illustrated
diagrams, graphs, tables in b/w/color.
ISBN:
0793-6643
| Price - Title 17 - Part 3 |
USD$
|
| Members per CD (Ext Plans) |
1599.00
|
| Non-members |
1999.00
|
 |
 |
 |
 |
 |
 |
| Ready-To-Go Link
| Handbook Series | Journal
Index | Specialized Journals
| Title
17 Calandar |
